We are live on
!
Find out more
RMCM
Reynders McVeigh Capital Management Portfolio holdings
AUM
$1.98B
1-Year Est. Return
23.37%
This Fund
S&P 500
This Quarter
Est. Return
+14.94%
1 Year Est. Return
+23.37%
3 Year Est. Return
+85.22%
5 Year Est. Return
+113.19%
10 Year Est. Return
+523.93%
AUM
$2B
AUM Growth
+$212M
(+12%)
Cap. Flow
+$4.26M
Cap. Flow
% of AUM
0.21%
Top 10 Holdings %
Top 10 Hldgs %
39.9%
Holding
201
New
8
Increased
67
Reduced
103
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$24.8M |
| 2 |
Unilever
UL
|
+$10.8M |
| 3 |
Rocket Companies
RKT
|
+$8.62M |
| 4 |
Salesforce
CRM
|
+$5.13M |
| 5 |
Applied Materials
AMAT
|
+$3.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$16.6M |
| 2 |
NVIDIA
NVDA
|
+$7.65M |
| 3 |
Automatic Data Processing
ADP
|
+$4.64M |
| 4 |
Aptiv
APTV
|
+$4.21M |
| 5 |
Tesla
TSLA
|
+$3.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.3% |
| 2 | Healthcare | 17.84% |
| 3 | Industrials | 16.88% |
| 4 | Consumer Discretionary | 9.64% |
| 5 | Communication Services | 7.68% |
Similar funds
SC
CAM
TCM
RCM
LGM
MYAM
HA
NIM
Reynders McVeigh Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Reynders McVeigh Capital Management held 201 positions worth $2B, up 12% from $1.79B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Reynders McVeigh Capital Management's Q2 2025 filing shows 8 new, 67 increased, 103 reduced and 6 closed positions. Its largest new stake was Novo Nordisk: 363,889 shares worth $25.1M. The largest sale was Medtronic, an estimated $16.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 33% a quarter earlier, followed by Healthcare and Industrials.
- Reynders McVeigh Capital Management's largest Q2 2025 buy was Novo Nordisk: 363,889 shares worth $25.1M.
- Reynders McVeigh Capital Management added most to Unilever in Q2 2025, an estimated $10.8M increase.
- Reynders McVeigh Capital Management's biggest Q2 2025 reduction was Medtronic, cutting an estimated $16.6M.
- Reynders McVeigh Capital Management fully exited Teradyne in Q2 2025, selling an estimated $1.26M.
- Reynders McVeigh Capital Management's ten largest holdings make up 40% of its $2B portfolio in Q2 2025.
- Reynders McVeigh Capital Management opened 8 new positions and closed 6 in Q2 2025.
- Reynders McVeigh Capital Management's portfolio value rose 12% quarter-over-quarter to $2B.
Based on Reynders McVeigh Capital Management's 13F filing for Q2 2025, filed 4 Sep 2025.